Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-039326
Filing Date
2020-08-11
Accepted
2020-08-11 16:23:07
Documents
50
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 Q2 20202 10-Q snss-10q_20200630.htm 10-Q 1658036
2 EX-10.1 snss-ex101_13.htm EX-10.1 73940
3 EX-10.2 snss-ex102_12.htm EX-10.2 94747
4 EX-31.1 snss-ex311_9.htm EX-31.1 16726
5 EX-32.1 snss-ex321_8.htm EX-32.1 6751
6 GRAPHIC gwr3lur3wetk000001.jpg GRAPHIC 3336
  Complete submission text file 0001564590-20-039326.txt   4458863

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT snss-20200630.xml EX-101.INS 628505
8 XBRL TAXONOMY EXTENSION SCHEMA snss-20200630.xsd EX-101.SCH 37346
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE snss-20200630_cal.xml EX-101.CAL 42135
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snss-20200630_def.xml EX-101.DEF 111760
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE snss-20200630_lab.xml EX-101.LAB 293861
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snss-20200630_pre.xml EX-101.PRE 205597
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Filer) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 201092729
SIC: 2834 Pharmaceutical Preparations